Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

摘要: Purpose There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated vascular endothelial growth factor (VEGF) –targeted therapy. Methods Baseline characteristics and outcomes 645 anti-VEGF therapy–naive RCC were collected from three US four Canadian cancer centers. Cox proportional hazards regression, followed by bootstrap validation, was used to identify independent OS. Results The median OS the whole cohort 22 months (95% CI, 20.2 26.5 months), follow-up 24.5 months. Overall, 396, 200, 49 sunitinib, sorafenib, bevacizumab, respectively. Four of five adverse according Memorial Sloan-Kettering Cancer Center (MSKCC) predictors short survival: hemoglobin less than lower limit normal (P < .0001), corrected calcium greater upper (U...